Lenvatinib in advanced thyroid, salivary gland, endometrial, and hepatocellular carcinomas: a real-world study on treatment duration and toxicity management.

Ther Adv Med Oncol · 2025 · PMC12432319 · PMID 40948908

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

All groups showed a trend of BMI decrease across lenvatinib treatment, with the highest delta found in AdCC (−3.9), followed by DTC (−1.49), EC (−1.0), and HCC (–0.78).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.